Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Apr 13, 2022

Keywords

ClinConnect Summary

The XCVD study is looking at how hormone replacement therapy (HRT) affects the gut microbiome—this is the community of bacteria and other microorganisms living in our intestines—and how these changes might relate to heart health in transgender individuals. Over two years, researchers will follow 200 healthy transgender people aged 18 to 50 who are undergoing HRT, examining how their gut health might influence the risk of developing heart disease.

To participate in this study, individuals need to be between 18 and 50 years old, speak either German or English, and have previously received gender hormone therapy. Participants will need to provide written consent and have health insurance to cover any unexpected findings during the study. Throughout the trial, participants can expect regular check-ups and tests to monitor their health, specifically looking at their gut microbiome, immune system, and potential cardiovascular risk factors. This study aims to help us better understand the relationship between hormones, gut health, and heart disease, which could lead to improved healthcare for transgender individuals in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-50
• • Language requirements: German, English
• • Previous gender hormone replacement therapy (HRT).
• • Ability to give consent and written consent to participate.
• • Health insurance (for clarification of incidental findings)
• Exclusion Criteria:
• • Diseases or functional disorders that, in the opinion of the study physician, preclude participation in the study.
• • Incapacity or other circumstances that do not allow study participants to fully understand the nature, significance and scope of this study.